Home/Biosimilar Atlas/Bevacizumab/Reliance Life Sciences bevacizumab

Reliance Life Sciences bevacizumab

Bevacizumab biosimilar developed by Reliance Life Sciences. Reference product Avastin.

Brands by market: Brand not published by CDSCO (India) ยท Commercial partner or holder: Reliance Life Sciences
FDAnot listed
EMAnot listed
CDSCOJan 2016permitted
EDEnot listed

Status by market

FDA

United States

Not listed by FDA.

EMA

European Union

Not listed by EMA.

CDSCO

India

Central Drugs Standard Control OrganisationApproved
Brand
Not published by CDSCO (INN only)
Holder or applicant
Reliance Life Sciences Pvt Ltd
Pathway
Similar Biologic, manufacture and marketing permission
Approved
Jan 2016
Application or permission
MF-48/2016; BULK-49/2016; additional indication MF/BIO/23/000098
Indications as licensed
Metastatic colorectal cancer at permission; hepatocellular carcinoma with atezolizumab added November 2023
Presentations
100 mg/4 mL and 400 mg/16 mL
Note
First bevacizumab biosimilar permitted anywhere.
Source
S014
EDE

United Arab Emirates

Not listed by EDE.

Chronology

Sources

All bevacizumab biosimilars

Planning bevacizumab biosimilar development?

EvySaif can help assess your regulatory pathway, clinical evidence requirements and market-entry strategy across India, UAE and other target markets.

Talk to a biosimilar regulatory consultant
Data current to September 2026.